News

How Soon Will The Johnson & Johnson Vaccine Arrive?

A third vaccine may be here soon.

by Isabella Bridie DeLeo
Updated: 
Originally Published: 
Johnson & Johnson vaccine
Getty

There’s some potentially very good news on the way in the fight to combat the coronavirus

pandemic: A third COVID-19 vaccine could soon be heading into American’s arms in a very short period of time. The Johnson & Johnson vaccine is vying for governmental approval. Here’s what you need to know about when you might be able to get it.

Here’s When The Johnson & Johnson Vaccine Could Be Available

Johnson & Johnson submitted an emergency use authorization application earlier this month from the Food and Drug Administration, and in a few weeks, on February 26, the FDA is set to meet with advisors to discuss the application and potentially approve the vaccine. A decision will likely follow very shortly after that. Based on the speed with which the Pfizer vaccine began distribution after being approved, that could mean that the Johnson & Johnson vaccine might be beginning to ship in a matter of weeks, not months, but only time will tell.

That could be some great news to look forward to amid what has thus far been a slow and sometimes hectic vaccine rollout. According to a statement, Johnson & Johnson plans to distribute 100 million doses in the first half of 2021, which could be an ambitious and tremendous help in curbing the spread of COVID-19.

How Does This Vaccine Compare to the Others Already Available?

The Johnson & Johnson vaccine only requires one jab in the arm, unlike the Moderna and Pfizer vaccines which require two doses administered several weeks apart. Additionally, this vaccine has a longer shelf life. According to NPR, “Unlike Pfizer and Moderna, Johnson & Johnson’s Janssen vaccine can be stored for at least three months at 36-46 degrees Fahrenheit, compatible with standard vaccine distribution channels.”

How Effective Is It?

The vaccine is 66% effective overall in combating severe and moderate cases four weeks after the dose has been administered. This translates to a 72% effectiveness in the U.S. and is expected to fare slightly less well in Latin America, where it is 66% effective, and South Africa, where it is 57% effective. is not as effectiveHowever, and quite crucially, it is 85% effective at preventing severe disease and is expected to become more effective over time (after 49 days, vaccinated trial participants did not report any positive COVID-19 cases). In comparison, the Pfizer vaccine is estimated to be around 95% effective and the Moderna is 94.5% effective, according to The New York Times.

What Does This Mean for COVID-19?

Paul Stoffels, the Johnson & Johnson vice chairman of the executive committee and chief scientific officer, said, “The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response,” according to

NPR. Stoffels added, “Eighty-five percent efficacy in preventing severe COVID-19 disease and prevention of COVID-19-related medical interventions will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19.” Hopefully, if approved, the Johnson & Johnson vaccine will begin its rollout soon, and more people can get vaccinated more quickly, ensuring herd immunity quickly.

This article was originally published on

Get More Great Content
Sign up for the Fatherly newsletter to get expert advice about fitness, gear, travel, style, parenting, and more in your inbox.
By subscribing to this BDG newsletter, you agree to our Terms of Service and Privacy Policy